摘要
目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者治疗前的18氟脱氧葡萄糖(18F-deoxyglucose,18 FDG) PET/CT标准摄取值(standard uptake value, SUV)与临床分期、原发肿瘤大小及病理学类型的关系。方法:对75例治疗前的NSCLC患者接受18FDG PET/CT检查获得最高SUV (SUVmax)。分析SUVmax与临床分期、原发肿瘤分期、肿瘤大小和病理学类型的关系,并研究SUV在四者组内差异是否有统计学意义。结果:SUVmax与临床分期和原发肿瘤大小均呈正相关(r=0.279,P=0.014;r= 0.645,P=0.001),与肿瘤病理学类型无关(r=-0.077,P=0.507);SUV在两组不同大小肿瘤组(≤3.0 cm和>3.0 cm)间差异有统计学意义,t=-0.647,P=0.015,在各个临床分期组(ⅠA~ⅡB、ⅢA和m B~Ⅳ)间差异有统计学意义,F=3.807,P=0.027,在4个原发肿瘤分期组(T1、T2、T3和T4)间差异有统计学意义,F=8.025,P=0.022,而在不同病理学类型组(鳞癌、腺癌和腺鳞癌)间差异无统计学意义,F=1.911,P=0.155。结论:18FDG PET/CT SUV随肿瘤大小和病期的增加呈升高趋势,可以作为评价NSCLC临床分期的辅助手段,但不能为无法取得病理学诊断的患者提供帮助。
OBJECTIVE: To investigate the correlation between standard uptake value (SUV) of ^18F-fluorodeoxyglucose Positron Emission Tomography (^18FDG PET/CT ) and the clinical staging, primary tumor size, pathological type of non-small cell lung cancer (NSCLC) patients who received the examination of ^18FDG PET/CT before the treatment. METHODS: 75 patients with biopsy-proven NSCLC were included in the protocol. All cases had whole body ^18FDG PET/CT scans prior to the treatment. Maximal SUVs (SUVmax) which were obtained by selecting a small region of interest (ROI) were used in the analysis. RESULTS: Clinical staging was positively related to SUV, r = 0. 279, P = 0. 014; SUVs were obviously different among the three clinical staging groups by single factor analysis of variance, F= 3. 807, P = 0. 027. The correlation between SUV and the two groups standed for primary tumor size were observed, r=0. 645, P=0. 001. Independent t-test showed that there were significant differences in SUV between the two groups, t= -0. 647, P= 0. 015. Single factor analysis of variance showed that SUVs were different among four T staging groups, F=8. 025, P=0. 022. However, the correlation between SUV and pathological type had no statistical difference, r=-0. 077, P=0. 507, and single factor analysis of variance demonstrated adverse outcome among the pathological type groups, F = 1. 911, P = 0. 155. CONCLUSIONS: Both primary tumor size and clinical staging of NSCLC can be evaluated by ^18FDG PET/CT SUV, but pathological type of NSCLC is not related to SUV.
出处
《中华肿瘤防治杂志》
CAS
2006年第24期1879-1881,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
山东省自然科学基金(Y2002 C25)